Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 7, 2004, Pages 705-710

  Gilissen, Lennard P L ^a,d   Derijks, Luc J J ^a   Bos, Laurens P ^a   Verhoeven, Herman M J M ^a   Bus, Paul J ^b   Hooymans, Piet M ^c   Engels, Leopold G J B ^a  

^a Sittard Geleen Heerlen   (Netherlands)

^b LAURENTIUS HOSPITAL   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

6 mercaptopurine; 6 thioguanine; Azathioprine; Crohn's disease; Therapeutic drug monitoring; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BETAMETHASONE; BUDESONIDE; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; PREDNISONE; STEROID; TIOGUANINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; ENTERITIS; ENZYME ACTIVITY; FEMALE; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; METHYLATION; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; TREATMENT REFUSAL;

EID: 3142628214     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000108333.52416.63     Document Type: Article

References (36)

1. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123:132-142.
2. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996; 91:423-433.
3. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85:717-722.
4. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43:329-339.
5. Hanauer SB, Meyers SM. Management of Crohn's disease in adults. Am J Gastroenterol 1997; 92:559-566.
6. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37:674-678.
7. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term randomised double-blind study. N Engl J Med 1980; 302:981-987.
8. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001; 48:591-592.
9. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39:401-406.
10. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théoret J, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.
11. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49:665-670.
12. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36:71-76.
13. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48:642-646.
14. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115:813-821.
15. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Koerelitz Bl. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989; 111:641-649.
16. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34:1081-1085.
17. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine. Aliment Pharmacol Ther 2000; 14:1561-1565.
18. McGovern DP, Travis SPL, Duley J, el Shobowale-Bakre M, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122: 838-839.
19. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, ParkHah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62:60-73.
20. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51:143-146.
21. Lennard L. Clinical implications of thiopurine methyltransferase- optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20:527-531.
22. Derijks LJJ, Gilissen LPL, Engels LGJB, Bos LP, Bus PJ, Lohman JJHM, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit; 26:311-318.
23. Lennard L, Singleton HJ. High performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-mercaptopurine metabolites in a single sample. J Chromatogr 1992; 583:83-90.
24. Truelove SC, Wilts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955; 4947:1041-1048.
25. Derijks LJJ, De Jong DJ, Gilissen LPL, Engels LGJB, Hooymans PM, Jansen JBMJ, Mulder CJJ. 6-Thioguanine seems promising in azathioprine-or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15:63-67.
26. Dubinsky MC, Huiying Y, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122:904-915.
27. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7:181-189.
28. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternative thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98: 1058-1063.
29. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tan T, Martin P, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303.
30. Naber AH, Van Haelst U, Yap SH. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991; 12:94-99.
31. Deleve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrolatine in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23:589-599.
32. De Jong DJ, Derijks LJJ, Gilissen LPL, Engels LGJB, De Boer SY, Hooymans PM, et al. Maintenance treatment with 6-thioguanine over one year in azathioprine or 6-mercaptopurine intolerant IBD patients [Abstract]. Gut 2003; 52 (suppl VI):A58.
33. Stork LC, Broxson EH, Sather H. Oral 6-thioguanine causes late onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia [Abstract]. Gastroenterology 2002; 122:T833.
34. Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behren C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12:429-436.
35. Kaskas BA, Louis E, Hindorf U, Schaeffeler E, Deflandre J, Graepler F, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52:140-142.
36. Derijks LJJ, Curvers WL, Hooymans PM, Van Deventer SJH, Hommes DW. No predictive value of thiopurine S-methyltransferase genotyping for myelosuppression or hepatotoxicity in inflammatory bowel disease patients established on azathioprine [Abstract]. Gut 2003; 52 (suppl VI): A58.